Skip to main content
main-content

28-09-2020 | Neuro-oncology | Video

ESMO 2020 | Entrectinib has durable CNS activity in patients with NTRK fusion-positive tumors

Thomas John discusses a pooled analysis of data from three early-phase trials showing the intracranial efficacy of entrectinib in patients with solid tumors and central nervous system metastases (5:33).

Funding for independent interviews at ESMO 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits